TRINA SINGLETERRY: Open Payments
NPI 1417487547 · NORTH LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$883 in 42 payments from 16 companies in 2025. Trend: 2023 $1,230 · 2024 $954 · 2025 $883
Food & beverage: $883
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $168 |
| Neurocrine BioSciences, Inc. | 1 | $129 |
| Teva Pharmaceuticals USA, Inc. | 4 | $106 |
| E.R. Squibb & Sons, L.L.C. | 4 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $74 |
| Lundbeck LLC | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Sage Therapeutics, LLC | 2 | $33 |
| Indivior Inc. | 1 | $32 |
| Alkermes, Inc. | 1 | $27 |
Products named: REXULTI, INGREZZA, COBENFY, ABILIFY ASIMTUFII, CAPLYTA, AUSTEDO XR, TRINTELLIX, UZEDY.
Industry payments across NV — which companies pay providers there.
